• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰腺癌中的免疫微环境。

The Immune Microenvironment in Pancreatic Cancer.

机构信息

Institute for Medical Microbiology and Hospital Hygiene, Philipps University Marburg, 35043 Marburg, Germany.

Institute of Pathology, University Hospital Giessen-Marburg, 35043 Marburg, Germany.

出版信息

Int J Mol Sci. 2020 Oct 3;21(19):7307. doi: 10.3390/ijms21197307.

DOI:10.3390/ijms21197307
PMID:33022971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7583843/
Abstract

The biology of solid tumors is strongly determined by the interactions of cancer cells with their surrounding microenvironment. In this regard, pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) represents a paradigmatic example for the multitude of possible tumor-stroma interactions. PDAC has proven particularly refractory to novel immunotherapies, which is a fact that is mediated by a unique assemblage of various immune cells creating a strongly immunosuppressive environment in which this cancer type thrives. In this review, we outline currently available knowledge on the cross-talk between tumor cells and the cellular immune microenvironment, highlighting the physiological and pathological cellular interactions, as well as the resulting therapeutic approaches derived thereof. Hopefully a better understanding of the complex tumor-stroma interactions will one day lead to a significant advancement in patient care.

摘要

实体肿瘤的生物学特性主要由癌细胞与其周围微环境的相互作用决定。在这方面,胰腺癌(胰腺导管腺癌,PDAC)是多种可能的肿瘤-基质相互作用的典型范例。PDAC 对新型免疫疗法特别具有抗性,这一事实是由各种免疫细胞的独特组合介导的,这些免疫细胞形成了强烈的免疫抑制环境,使这种癌症类型得以生长。在这篇综述中,我们概述了目前关于肿瘤细胞与细胞免疫微环境之间相互作用的知识,强调了生理和病理细胞相互作用,以及由此产生的治疗方法。希望对复杂的肿瘤-基质相互作用有更深入的了解,有朝一日能为患者护理带来重大进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7896/7583843/7a38b74b275b/ijms-21-07307-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7896/7583843/72000a106caf/ijms-21-07307-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7896/7583843/833282f7eb0d/ijms-21-07307-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7896/7583843/a606caac85f1/ijms-21-07307-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7896/7583843/0dc77748d202/ijms-21-07307-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7896/7583843/8fa388dc9872/ijms-21-07307-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7896/7583843/7a38b74b275b/ijms-21-07307-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7896/7583843/72000a106caf/ijms-21-07307-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7896/7583843/833282f7eb0d/ijms-21-07307-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7896/7583843/a606caac85f1/ijms-21-07307-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7896/7583843/0dc77748d202/ijms-21-07307-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7896/7583843/8fa388dc9872/ijms-21-07307-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7896/7583843/7a38b74b275b/ijms-21-07307-g006.jpg

相似文献

1
The Immune Microenvironment in Pancreatic Cancer.胰腺癌中的免疫微环境。
Int J Mol Sci. 2020 Oct 3;21(19):7307. doi: 10.3390/ijms21197307.
2
Strategies for Increasing Pancreatic Tumor Immunogenicity.增强胰腺肿瘤免疫原性的策略。
Clin Cancer Res. 2017 Apr 1;23(7):1656-1669. doi: 10.1158/1078-0432.CCR-16-2318.
3
Pancreatic ductal adenocarcinoma microenvironment: Soluble factors and cancer associated fibroblasts as modulators of NK cell functions.胰腺导管腺癌微环境:可溶性因子和癌相关成纤维细胞作为 NK 细胞功能的调节剂。
Immunol Lett. 2024 Oct;269:106898. doi: 10.1016/j.imlet.2024.106898. Epub 2024 Jul 15.
4
An Immunological Glance on Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌的免疫学观察。
Int J Mol Sci. 2020 May 8;21(9):3345. doi: 10.3390/ijms21093345.
5
Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.免疫治疗胰腺导管腺癌的最新进展和展望。
Mol Cancer. 2020 Feb 15;19(1):32. doi: 10.1186/s12943-020-01151-3.
6
Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.靶向肿瘤微环境用于胰腺癌治疗
Chin Clin Oncol. 2019 Apr;8(2):18. doi: 10.21037/cco.2019.03.02.
7
Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells.新辅助治疗通过耗竭促肿瘤免疫细胞重塑胰腺癌微环境。
Clin Cancer Res. 2020 Jan 1;26(1):220-231. doi: 10.1158/1078-0432.CCR-19-1864. Epub 2019 Oct 4.
8
Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer.免疫细胞对细胞外基质的调节作用有助于胰腺癌的发病机制。
Biomolecules. 2021 Jun 17;11(6):901. doi: 10.3390/biom11060901.
9
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?胰腺导管腺癌的免疫治疗:我们现在在哪里?
World J Gastroenterol. 2018 May 28;24(20):2137-2151. doi: 10.3748/wjg.v24.i20.2137.
10
Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review.免疫检查点抑制治疗胰腺导管腺癌:局限性与展望:系统综述。
Cell Commun Signal. 2021 Nov 24;19(1):117. doi: 10.1186/s12964-021-00789-w.

引用本文的文献

1
The effect of CD40 agonist antibody therapy on the pancreatic cancer microenvironment.CD40激动剂抗体疗法对胰腺癌微环境的影响。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Sep 10. doi: 10.1007/s00210-025-04532-x.
2
The immune-related prognostic gene AIM2 promotes pancreatic cancer progression via inflammasome.免疫相关预后基因AIM2通过炎性小体促进胰腺癌进展。
Sci Rep. 2025 Aug 13;15(1):29733. doi: 10.1038/s41598-025-12651-x.
3
The Aging Microenvironment as a Determinant of Immune Exclusion and Metastatic Fate in Pancreatic Cancer.

本文引用的文献

1
The dark side of immunotherapy: pancreatic cancer.免疫疗法的阴暗面:胰腺癌
Cancer Drug Resist. 2020 May 11;3(3):491-520. doi: 10.20517/cdr.2020.13. eCollection 2020.
2
The Oncoprotein SKI Acts as A Suppressor of NK Cell-Mediated Immunosurveillance in PDAC.癌蛋白SKI在胰腺癌中作为自然杀伤细胞介导的免疫监视的抑制因子。
Cancers (Basel). 2020 Oct 3;12(10):2857. doi: 10.3390/cancers12102857.
3
Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification.胰腺导管内黏液性肿瘤:基于肿瘤生物学的风险分层方法
衰老微环境作为胰腺癌免疫排斥和转移命运的决定因素
bioRxiv. 2025 May 10:2025.05.08.652966. doi: 10.1101/2025.05.08.652966.
4
Semi-permeable polymer vesicle-based prooxidative and lactate-depleting nanoreactors with sustained activity against pancreatic cancer.基于半透性聚合物囊泡的具有持续抗胰腺癌活性的促氧化和乳酸消耗纳米反应器
Front Bioeng Biotechnol. 2025 Jun 26;13:1626927. doi: 10.3389/fbioe.2025.1626927. eCollection 2025.
5
Deep Exploration of the Immunopeptidome of a Pancreatic Cancer Cell Line: Implications for Clinical Immunopeptidomics and Immunotherapy.胰腺癌细胞系免疫肽组的深入探索:对临床免疫肽组学和免疫治疗的意义
Mol Cell Proteomics. 2025 Jul 8;24(8):101030. doi: 10.1016/j.mcpro.2025.101030.
6
CRO-67 has anti-cancer activity in pancreatic tumor cells and stromal cancer-associated fibroblasts.CRO - 67在胰腺肿瘤细胞和基质癌相关成纤维细胞中具有抗癌活性。
Sci Rep. 2025 Jul 8;15(1):24488. doi: 10.1038/s41598-025-09411-2.
7
Spatial proteomics and transcriptomics reveal early immune cell organization in pancreatic intraepithelial neoplasia.空间蛋白质组学和转录组学揭示胰腺上皮内瘤变中早期免疫细胞组织。
JCI Insight. 2025 Jun 26;10(15). doi: 10.1172/jci.insight.191595. eCollection 2025 Aug 8.
8
Innate Immunity and Platelets: Unveiling Their Role in Chronic Pancreatitis and Pancreatic Cancer.先天性免疫与血小板:揭示它们在慢性胰腺炎和胰腺癌中的作用
Cancers (Basel). 2025 May 17;17(10):1689. doi: 10.3390/cancers17101689.
9
The Interplay Between DNA Repair and the Immune Microenvironment in Pancreatic Cancer.胰腺癌中DNA修复与免疫微环境之间的相互作用
Biomedicines. 2025 Apr 24;13(5):1031. doi: 10.3390/biomedicines13051031.
10
Unveiling the immunological terrain of pancreatic ductal adenocarcinoma: strategies to prompt immunotherapy from Mendelian randomization.揭示胰腺导管腺癌的免疫格局:基于孟德尔随机化促进免疫治疗的策略
Discov Oncol. 2025 Apr 25;16(1):613. doi: 10.1007/s12672-025-02250-7.
Int J Mol Sci. 2020 Sep 2;21(17):6386. doi: 10.3390/ijms21176386.
4
Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer.白细胞介素-17 诱导的中性粒细胞胞外陷阱介导胰腺癌对检查点阻断的抵抗。
J Exp Med. 2020 Dec 7;217(12). doi: 10.1084/jem.20190354.
5
Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment.胰腺癌的新型联合免疫疗法:CD40激动剂与白细胞介素-15治疗具有强大的抗肿瘤作用
Clin Transl Immunology. 2020 Aug 15;9(8):e1165. doi: 10.1002/cti2.1165. eCollection 2020.
6
Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer.患者来源类器官药物代谢定型是一种用于胰腺癌精准医疗的临床可行策略。
Ann Surg. 2020 Sep 1;272(3):427-435. doi: 10.1097/SLA.0000000000004200.
7
CD200 promotes immunosuppression in the pancreatic tumor microenvironment.CD200 促进胰腺肿瘤微环境中的免疫抑制。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2019-000189. Epub 2020 Jun 23.
8
Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC).中性粒细胞与淋巴细胞比值(NLR)与胰腺导管腺癌(PDAC)患者的预后和免疫调节有关。
Biosci Rep. 2020 Jun 26;40(6). doi: 10.1042/BSR20201190.
9
CXCL10 and CCL21 Promote Migration of Pancreatic Cancer Cells Toward Sensory Neurons and Neural Remodeling in Tumors in Mice, Associated With Pain in Patients.CXCL10 和 CCL21 促进胰腺癌细胞向感觉神经元迁移和肿瘤内的神经重塑,与患者疼痛相关。
Gastroenterology. 2020 Aug;159(2):665-681.e13. doi: 10.1053/j.gastro.2020.04.037. Epub 2020 Apr 21.
10
TGF-β1 secreted by pancreatic stellate cells promotes stemness and tumourigenicity in pancreatic cancer cells through L1CAM downregulation.胰腺星状细胞分泌的 TGF-β1 通过下调 L1CAM 促进胰腺癌干细胞特性和致瘤性。
Oncogene. 2020 May;39(21):4271-4285. doi: 10.1038/s41388-020-1289-1. Epub 2020 Apr 14.